Hydroxycarteolol

{{short description|Chemical compound}}

{{Infobox drug

| drug_name =

| IUPAC_name = 8-Hydroxy-5-{2-hydroxy-3-[(2-methyl-2-propanyl)amino]propoxy}-3,4-dihydro-2(1H)-quinolinone

| image = 8-Hydroxycarteolol.svg

| alt =

| caption =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 59826-22-1

| ATCvet =

| ATC_prefix = None

| ATC_suffix =

| PubChem = 124688

| ChemSpiderID = 111020

| ChEBI = 192312

| DrugBank =

| synonyms = 8-Hydroxycarteolol

| C=16 | H=24 | N=2 | O=4

| smiles = O=C2Nc1c(O)ccc(OCC(O)CNC(C)(C)C)c1CC2

| StdInChI = 1S/C16H24N2O4/c1-16(2,3)17-8-10(19)9-22-13-6-5-12(20)15-11(13)4-7-14(21)18-15/h5-6,10,17,19-20H,4,7-9H2,1-3H3,(H,18,21)

| StdInChIKey = TVZJLAKRXHGVOK-UHFFFAOYSA-N

}}

Hydroxycarteolol is a beta blocker and metabolite of carteolol.{{cite journal | title = A comparison of the opacifying effects of carteolol.HCl and 8-hydroxycarteolol.HCl in the isolated porcine cornea |vauthors=Igarashi H, Katsuta Y, Sawa K, Nakazato Y, Kawasaki T | journal = Fundam Appl Toxicol | date = Apr 1990 | volume = 14 | issue = 3 | pages = 554–559 | pmid=2340982 | doi=10.1093/toxsci/14.3.554}}{{cite journal | title = The beta-adrenoceptor antagonist carteolol and its metabolite 8-hydroxycarteolol have different intrinsic sympathomimetic activities |vauthors=Jasper JR, Michel MC, Insel PA | journal =Br J Clin Pharmacol | year = 1990 | volume = 30 | issue = Suppl 1 | pages = 109S–111S | pmid= 2176514 | pmc=1368107 | doi=10.1111/j.1365-2125.1990.tb05477.x}}